Tonix Pharmaceuticals Holding Corp.
TNXP
$16.88
-$0.42-2.43%
| Weiss Ratings | TNXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | TNXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TNXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.04 | |||
| Price History | TNXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.93% | |||
| 30-Day Total Return | 114.76% | |||
| 60-Day Total Return | -27.34% | |||
| 90-Day Total Return | -11.02% | |||
| Year to Date Total Return | -46.24% | |||
| 1-Year Total Return | -96.90% | |||
| 2-Year Total Return | -99.85% | |||
| 3-Year Total Return | -99.99% | |||
| 5-Year Total Return | -100.00% | |||
| 52-Week High % Change | -97.43% | |||
| 52-Week Low % Change | 155.92% | |||
| Price | TNXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $672.00 | |||
| 52-Week Low Price | $6.76 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | May 17, 2024 | |||
| Valuation | TNXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 111.32M | |||
| Enterprise Value | 20.67M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2,552.08 | |||
| Earnings Per Share Growth | 17.08% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.88 | |||
| Price/Book (Q) | 0.54 | |||
| Enterprise Value/Revenue (TTM) | 2.05 | |||
| Price | $16.88 | |||
| Enterprise Value/EBITDA (TTM) | -0.28 | |||
| Enterprise Value/EBIT | -0.27 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | TNXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 2.26M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TNXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 862 799 8599 | |||
| Address | 26 Main Street Chatham, NJ 07928 | |||
| Website | www.tonixpharma.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | TNXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -770.20% | |||
| Profit Margin | -1,288.25% | |||
| Management Effectiveness | TNXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -30.62% | |||
| Return on Equity | -- | |||
| Income Statement | TNXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 10.09M | |||
| Total Revenue (TTM) | 10.09M | |||
| Revenue Per Share | $4.46 | |||
| Gross Profit (TTM) | 2.33M | |||
| EBITDA (TTM) | -74.32M | |||
| EBIT (TTM) | -77.74M | |||
| Net Income (TTM) | -130.04M | |||
| Net Income Avl. to Common (TTM) | -130.04M | |||
| Total Revenue Growth (Q YOY) | -31.68% | |||
| Earnings Growth (Q YOY) | 19.08% | |||
| EPS Diluted (TTM) | -2.55K | |||
| EPS Diluted Growth (Q YOY) | 99.55% | |||
| Balance Sheet | TNXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 98.78M | |||
| Cash Per Share (Q) | $43.64 | |||
| Total Current Assets (Q) | 119.00M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 139.56M | |||
| Current Ratio (Q) | 6.500 | |||
| Book Value Per Share (Q) | $31.82 | |||
| Total Assets (Q) | 162.89M | |||
| Total Current Liabilities (Q) | 18.31M | |||
| Total Debt (Q) | 8.12M | |||
| Total Liabilities (Q) | 23.33M | |||
| Total Common Equity (Q) | 139.56M | |||
| Cash Flow | TNXP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -120.00K | |||
| Cash from Financing (TTM) | 134.87M | |||
| Net Change in Cash (TTM) | 73.83M | |||
| Levered Free Cash Flow (TTM) | -38.18M | |||
| Cash from Operations (TTM) | -60.93M | |||
